A 37-year-old woman with grade 3 anaplastic astrocytoma (AA) of the left frontal lobe, underwent surgical excision, chemotherapy and external beam radiation therapy in 2004. After being in remission for 5 years, recurrence was suspected clinically when she presented with seizures. The result of contrast-enhanced magnetic resonance imaging (MRI) was equivocal for recurrence and radiation necrosis (not available). The patient was then referred for 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography-computed tomography (PET-CT), as the initial primary tumour was high grade in nature. 18 F-FDG PET-CT was negative for recurrence and demonstrated only post-operative changes in the left frontal region (Fig. 1a, b, arrow) . Due to strong clinical suspicion, 3,4-dihydroxy-6-18 F-fluoro-L -phenylalanine ( 18 F-FDOPA) PET-CT was done, 5 days after 18 F-FDG PET-CT. The study revealed an 18 F-FDOPA-avid mass lesion in the left frontal region (Fig. 1c, d , arrow), thereby confirming the presence of recurrent disease. The patient underwent surgical resection of the mass, and it was confirmed by histopathology as grade 3 AA. However, after a short asymptomatic period of 4 months the patient became symptomatic again. Follow-up MRI after 6 months of surgery revealed presence of ipsilateral and contralateral multifocal contrast enhancing recurrent mass lesions (Fig. 1e, f, arrow) , suggesting the progression of disease. The patient was started on temozolamide but she died after 8 months' follow-up.
Though MRI is routinely used in assessment of brain tumours, its ability to differentiate between treatmentinduced changes and residual or recurrent tumour is limited [1] . 18 F-FDG PET was the first tracer used for assessment of brain tumours [2] ; however, it has a low tumour-to-background ratio in brain, limiting its utility. 18 F-FDG uptake correlates with tumour grade, with highgrade gliomas (grades III and IV) showing higher uptake than low-grade gliomas [3, 4] . Therefore, in spite of its limitations, 18 F-FDG PET-CT is used for imaging of highgrade glioma. Amino acid PET radiotracers including 18 F-FDOPA display superior contrast to 18 F-FDG because of low uptake of amino acids in normal brain tissue [5] . They have particularly special value in the detection of low-grade gliomas [6] . However, 18 F-FDOPA tumour uptake cannot provide reasonable predictions about tumour grade and proliferation in recurrent tumours that have undergone treatments [7] . Also, their difficult synthesis or need for an on-site cyclotron limits their widespread use. The present case shows the utility of 18 F-FDOPA PET-CT in detection of a recurrent high-grade AA that was missed by 18 F-FDG PET-CT. It highlights that 18 F-FDG PET-CT can be falsely negative, even in high-grade recurrent gliomas and, therefore, in cases with strong clinical suspicion 18 F-FDOPA PET-CT can be an alternative imaging modality to rule out recurrence even when 18 F-FDG PET-CT is negative. Fig. 1 a, b 18 F-FDG PET-CT. c, d
18 F-FDOPA. e, f Six-month follow-up MRI
